ProKidney

PROK

1.4101.40% ( -0.020 )

Closed: Oct 23, 16:00:00 (EDT)

Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: revenue of $150K slightly beat the $149K expectation, while GAAP EPS of -$0.15 missed the -$0.1387 mean estimate due to R&D acceleration. Operating loss of $48.4M was deeper than the expected $47.0M EBIT loss, driven by $36.1M in R&D spend as Phase 3 PROACT 1 clinical trials progressed. The company issued a 'going concern' warning, noting that its $181.6M in liquidity is insufficient to fund operations beyond mid-2027 without additional capital.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: ProKidney(PROK) the Revenue is 150 K (-32.13%), Beat estimate;the EBIT is -48.37 M (-21.82%), Miss estimate;the EPS is -0.15 (-15.38%), Miss estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.00B32.13%

0.00B32.58%

+0.00B0.45%

EBITMiss expectations

-0.05B21.82%

-0.05B18.28%

-0.00B3.54%

EPSMiss expectations

-0.1515.38%

-0.13876.68%

-0.01138.70%

Upcoming earnings report - Q3 FY2026

Available dateNov 10, 2026

Estimate Revenue$124.6 K

Estimate EBIT-$49.27 M

Estimate EPS-$0.1402

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly